Vinva Investment Management Ltd Cuts Stock Position in Boston Scientific Co. (NYSE:BSX)

Vinva Investment Management Ltd lowered its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 11.0% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 52,075 shares of the medical equipment provider's stock after selling 6,469 shares during the period. Vinva Investment Management Ltd's holdings in Boston Scientific were worth $4,340,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Triad Wealth Partners LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth $26,000. Values First Advisors Inc. acquired a new position in shares of Boston Scientific during the 3rd quarter worth $28,000. Andra AP fonden acquired a new position in shares of Boston Scientific during the 2nd quarter worth $29,000. Lynx Investment Advisory acquired a new position in shares of Boston Scientific during the 2nd quarter worth $30,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new stake in Boston Scientific during the 3rd quarter worth $30,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the sale, the executive vice president now owns 34,748 shares in the company, valued at approximately $2,913,967.28. This represents a 16.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 328,157 shares of company stock valued at $27,894,270. 0.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Citigroup boosted their price objective on Boston Scientific from $92.00 to $98.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th. Stifel Nicolaus boosted their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Bank of America boosted their price objective on Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. BTIG Research boosted their price objective on Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Finally, Mizuho boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $93.39.

Boston Scientific Stock Down 0.1 %

BSX stock traded down $0.09 during trading on Friday, reaching $90.66. 3,446,971 shares of the stock were exchanged, compared to its average volume of 6,066,885. The firm's 50 day moving average is $86.70 and its 200 day moving average is $80.71. Boston Scientific Co. has a twelve month low of $53.93 and a twelve month high of $91.93. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market cap of $133.62 billion, a P/E ratio of 74.93, a price-to-earnings-growth ratio of 2.67 and a beta of 0.79.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the prior year, the business earned $0.50 EPS. The firm's revenue for the quarter was up 19.3% on a year-over-year basis. As a group, research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.